A strong stock as of late has been United Fire Group (UFCS) . Shares have been marching higher, with the stock up 19.1% over the past month. The stock hit a new 52-week high of $36.7 in the previous session. United Fire has gained 27.5% since the start of the year compared to the 14.1% gain for the Zacks Finance sector and the 8.3% return for the Zacks Insurance - Property and Casualty industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, having beaten the Z ...

Have you been paying attention to shares of State Street Corporation (STT) ? Shares have been on the move with the stock up 4.8% over the past month. The stock hit a new 52-week high of $120.4 in the previous session. State Street has gained 22% since the start of the year compared to the 14.1% gain for the Zacks Finance sector and the 10.6% return for the Zacks Banks - Major Regional industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't m ...

Core Insights - Health Catalyst (HCAT) reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, but down from $0.07 per share a year ago [1][2] - The company achieved a revenue of $76.32 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.66%, and slightly down from $76.35 million year-over-year [3] Earnings Performance - The earnings surprise for the quarter was +20.00%, following a previous surprise of +33.33% when earnings were $0.04 per share against an expectation of $0.03 [2] - Over the last four quarters, Health Catalyst has exceeded consensus EPS estimates two times and revenue estimates three times [2][3] Stock Performance - Health Catalyst shares have declined approximately 60% since the beginning of the year, contrasting with the S&P 500's gain of 14.4% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $74.59 million, and for the current fiscal year, it is $0.19 on revenues of $309.8 million [8] - The Medical Info Systems industry, to which Health Catalyst belongs, is ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]

Company Performance - Symbotic Inc. closed at $70.72, with a daily increase of +1.32%, underperforming the S&P 500's gain of 1.54% [1] - The stock has increased by 9.47% over the past month, contrasting with a 6.8% loss in the Business Services sector and a 0.29% gain in the S&P 500 [1] Earnings Expectations - The company is expected to release earnings on November 24, 2025, with an anticipated EPS of $0.07, representing a 40% increase year-over-year [2] - Revenue is projected to be $600.16 million, reflecting a 4.05% increase compared to the same quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are estimated at $0.24 per share, indicating a 400% increase from the previous year, while revenue is expected to remain stable at $2.23 billion [3] Analyst Estimates - Recent modifications to analyst estimates for Symbotic Inc. indicate positive sentiment regarding the company's business and profitability [4] - The Zacks Rank system, which assesses these estimate changes, currently ranks Symbotic Inc. at 3 (Hold) [6] Valuation Metrics - Symbotic Inc. has a Forward P/E ratio of 175.6, significantly higher than the industry average of 21.19 [7] - The company also has a PEG ratio of 5.85, compared to the Technology Services industry's average PEG ratio of 1.6 [7] Industry Context - The Technology Services industry, part of the Business Services sector, holds a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [8]

In the latest close session, Samsara Inc. (IOT) was up +2.58% at $39.83. The stock outpaced the S&P 500's daily gain of 1.54%. Elsewhere, the Dow saw an upswing of 0.81%, while the tech-heavy Nasdaq appreciated by 2.27%. Coming into today, shares of the company had gained 5.34% in the past month. In that same time, the Computer and Technology sector gained 1.22%, while the S&P 500 gained 0.29%. Investors will be eagerly watching for the performance of Samsara Inc. in its upcoming earnings disclosure. The co ...

Core Viewpoint - Everus Construction Group, Inc. (ECG) shows potential as a strong investment opportunity due to significant revisions in earnings estimates, indicating a positive earnings outlook and potential for continued stock price appreciation [1][2]. Earnings Estimate Revisions - Analysts have increased their earnings estimates for ECG, reflecting growing optimism about the company's financial prospects, which is expected to positively influence its stock price [2][3]. - The current-quarter earnings estimate is $0.72 per share, representing a 7.5% increase from the previous year, with a notable 25.44% rise in the Zacks Consensus Estimate over the last 30 days due to two upward revisions [6]. - For the full year, the earnings estimate stands at $3.26 per share, marking a 16.0% increase from the prior year, with a 10.71% boost in the consensus estimate over the same period [7][8]. Zacks Rank and Performance - ECG has achieved a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance based on the positive earnings estimate revisions [9]. - Historically, stocks with a Zacks Rank 1 have generated an average annual return of +25% since 2008, suggesting that ECG may follow a similar trend [3][9]. Recent Stock Performance - ECG shares have appreciated by 18.1% over the past four weeks, reflecting investor confidence in the company's earnings growth prospects driven by favorable estimate revisions [10].

Core Viewpoint - Pharming Group N.V. Sponsored ADR (PHAR) shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][2]. Earnings Estimates - Analysts' optimism regarding Pharming Group's earnings prospects is leading to higher estimates, which is expected to positively impact the stock price [2]. - The Zacks Rank system indicates a strong correlation between earnings estimate revisions and stock price movements, with Pharming Group benefiting from this trend [2][3]. Current-Quarter Estimates - For the current quarter, Pharming Group is expected to earn $0.03 per share, reflecting a year-over-year decline of 40.0% [6]. - Over the past 30 days, one estimate has increased with no negative revisions, resulting in a 150% increase in the Zacks Consensus Estimate [6]. Current-Year Estimates - For the full year, the expected earnings per share for Pharming Group is $0.06, representing a year-over-year increase of 137.5% [7]. - The trend for current-year estimate revisions is positive, with one estimate moving higher and no negative revisions, leading to a 220% increase in the consensus estimate [8]. Zacks Rank - The favorable estimate revisions have earned Pharming Group a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance [9]. - Research shows that stocks with a Zacks Rank 1 and 2 significantly outperform the S&P 500 [9]. Investment Outlook - Pharming Group's stock has risen 8.1% over the past four weeks due to strong estimate revisions, suggesting further upside potential [10]. - Investors may consider adding Pharming Group to their portfolios based on the current positive momentum [10].

Core Viewpoint - Macy's is positioned well to continue its trend of beating earnings estimates, supported by a strong history of performance in recent quarters [1][2]. Earnings Performance - Macy's has consistently surpassed earnings estimates, achieving an average beat of 65.04% over the last two quarters [2]. - In the most recent quarter, Macy's reported earnings of $0.41 per share against an expectation of $0.19, resulting in a surprise of 115.79% [2]. - For the previous quarter, the company reported $0.16 per share, exceeding the consensus estimate of $0.14, which was a surprise of 14.29% [2]. Earnings Estimates and Predictions - Recent estimates for Macy's have been revised upward, indicating positive sentiment among analysts [5]. - The Zacks Earnings ESP for Macy's is currently +14.82%, suggesting bullish expectations for upcoming earnings [8]. - A positive Earnings ESP combined with a Zacks Rank of 1 (Strong Buy) indicates a high likelihood of another earnings beat [8]. Statistical Insights - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7]. Importance of Earnings ESP - Monitoring a company's Earnings ESP before quarterly releases is crucial for increasing the likelihood of successful investment decisions [10].

Core Insights - Braze, Inc. (BRZE) has a strong history of exceeding earnings estimates, with an average surprise of 220.00% over the last two quarters, indicating potential for continued performance in upcoming reports [1][2]. Earnings Performance - In the most recent quarter, Braze reported earnings of $0.15 per share, surpassing the expected $0.03 per share, resulting in a surprise of 400.00% [2]. - For the previous quarter, the company reported $0.07 per share against an expectation of $0.05 per share, yielding a surprise of 40.00% [2]. Earnings Estimates and Predictions - Estimates for Braze have been trending upward, supported by its history of earnings surprises, and the stock currently has a positive Zacks Earnings ESP of +10.53%, suggesting bullish sentiment among analysts [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a strong likelihood of another earnings beat [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7].

Core Insights - JD.com is expected to report third-quarter 2025 results on November 13, with revenue estimates at $41.33 billion, reflecting an 11.4% year-over-year growth, while earnings per share are projected at 46 cents, indicating a 62.9% decline from the previous year [1][9] Earnings Performance - In the last quarter, JD.com achieved an earnings surprise of 13.76%, consistently beating the Zacks Consensus Estimate over the past four quarters with an average surprise of 18.89% [2] Earnings Predictions - Current analysis indicates a negative Earnings ESP of -3.30% and a Zacks Rank of 3 (Hold), suggesting uncertainty regarding an earnings beat this quarter [3] Growth Factors - JD.com entered Q3 2025 with strong momentum, reporting a 22% year-over-year revenue growth in Q2, with active customer engagement increasing over 40% [4] Retail Performance - Continued strength in JD Retail is anticipated, with prior revenue growth of 21% and an operating margin of 4.5%. Categories like electronics and home appliances benefited from government trade-in incentives, while general merchandise showed steady growth [5][9] Food Delivery Segment - JD Food Delivery, launched in February, is expected to have expanded its logistics and merchant base, although high operating costs may have impacted profitability [6] Strategic Acquisition - JD announced a voluntary public takeover offer for CECONOMY AG, valued at EUR 2.2 billion, highlighting its international diversification strategy, though it may face regulatory and integration challenges [7][18] Stock Performance - JD.com shares have declined 8.3% year-to-date, underperforming compared to the Internet-Commerce industry and major indices, while competitors like Amazon and PDD Holdings have seen significant stock appreciation [10] Valuation Metrics - JD.com currently trades at a forward P/E ratio of 9.06X, significantly lower than the industry average of 25.33X, indicating a potentially undervalued position relative to expected earnings growth [13][18] Investment Considerations - JD.com shows stable growth prospects supported by retail demand and strategic diversification, but ongoing investments in logistics and international ventures may pressure near-term profitability [15][19]